4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $32.71 Consensus Target Price from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been given a consensus recommendation of “Moderate Buy” by the nine research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $32.7143.

Several equities research analysts have recently issued reports on the company. Royal Bank Of Canada raised their target price on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Chardan Capital restated a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Barclays began coverage on shares of 4D Molecular Therapeutics in a report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several institutional investors have recently bought and sold shares of FDMT. Dynamic Technology Lab Private Ltd purchased a new stake in 4D Molecular Therapeutics in the first quarter worth $39,000. Wexford Capital LP bought a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at $41,000. Quadrature Capital Ltd purchased a new position in shares of 4D Molecular Therapeutics during the 2nd quarter valued at $42,000. Farther Finance Advisors LLC lifted its position in shares of 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after buying an additional 2,674 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics during the 1st quarter worth $46,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Price Performance

FDMT stock opened at $9.33 on Friday. The firm has a market cap of $476.30 million, a PE ratio of -3.86 and a beta of 2.99. The business has a 50 day moving average of $8.93 and a 200-day moving average of $9.23. 4D Molecular Therapeutics has a 12-month low of $2.23 and a 12-month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative return on equity of 31.75% and a negative net margin of 164.43%.The business had revenue of $85.09 million for the quarter, compared to analyst estimates of $30.86 million. On average, research analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.